A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how long patients who undergo complete surgical
removal of recurrent osteosarcoma in the lung will remain free of cancer after taking
Saracatinib compared to patients taking placebo (a sugar pill).
Phase:
Phase 2
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration